中国临床药理学杂志2025，Vol.41Issue(6)：872-876,5.DOI:10.13699/j.cnki.1001-6821.2025.06.023
恩美曲妥珠单抗治疗HER2阳性转移性乳腺癌的快速卫生技术评估
Rapid health technology assessment of trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer
摘要
Abstract
Objective To evaluate the efficacy,safety,and economy of trastuzumab emtansine(T-DM1)in the treatment of human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer based on the rapid health technology assessment methodology,and to provide a reference for the rational use of the drug in the clinic.Methods A systematic search of Chinese and English databases such as PubMed,Embase,the Cochrane Library,CNKI,Wanfang,SinoMed,etc.was performed to screen the literature according to the inclusion and exclusion criteria,extract the data,evaluate the quality of the literature,and qualitatively analyze the results.Results T-DM1 had comparable or even superior efficacy in terms of progression-free survival(PFS)and overall survival(OS)compared with conventional anti-HER2 treatment regimens as well as other chemotherapeutic regimens.Some regimens,such as docetaxel+trastuzumab+patuximab,and pyrrolitinib+capecitabine,might be superior to T-DM1 in terms of PFS and OS.Adverse effects of T-DM1 were mainly liver function abnormalities and thrombocytopenia,and overall the safety profile was better,with a lower probability of serious adverse effects.In terms of economy,T-DM1 was more favorable than T-Dxd,and further evaluation was still needed compared with other regimens.Conclusion T-DM1 has favorable efficacy and safety,with economics to be further evaluated.关键词
恩美曲妥珠单抗/转移性乳腺癌/卫生技术评估Key words
trastuzumab emtansine/advanced breast cancer/health technology assessment分类
医药卫生引用本文复制引用
张志琪,张卓,刘倩欣,庞晓丛,周颖..恩美曲妥珠单抗治疗HER2阳性转移性乳腺癌的快速卫生技术评估[J].中国临床药理学杂志,2025,41(6):872-876,5.基金项目
国家卫生健康委医院管理研究所医疗质量(循证)管理研究基金资助项目(YLZLXZ23G030) （循证）
北京大学第一医院科研种子基金课题资助项目(2024SF58) （2024SF58）
